OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD

OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD (PR Newswire)

UF startup OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the long-term study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego.

“We are pleased to present the initial outcomes after a 52-week continuous treatment with Oxabact® in patients with Primary Hyperoxaluria treated with maintenance dialysis,” says Matthew Gantz, CEO of OxThera. “To our knowledge, study OC5-OL-01 represents the longest efficacy and safety data of any intervention to lower the oxalate burden in patients with PH1 to date. We are very encouraged that Oxabact® was able to lower plasma oxalate and normalize cardiac function, particularly since patients did not need an intensification of their dialysis regimen. We are excited about the potential of Oxabact® in helping patients with this devastating disease.”

Learn more about OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD.

X